FOLH1 and prostate adenocarcinoma: While targeting the prostate-specific membrane antigen (PSMA) has been increasingly established in the diagnosis and treatment of prostate adenocarcinoma, preclinical and early clinical studies are suggesting its limited utility in NEPC.